Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics
Yükleniyor...
Dosyalar
Tarih
2019
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
IVYSPRING INT PUBL
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.
Açıklama
Anahtar Kelimeler
Berberine, Cardiovascular diseases, Metabolic diseases, Targets, Therapeutics
Kaynak
THERANOSTICS
WoS Q Değeri
Q1
Scopus Q Değeri
Q1
Cilt
9
Sayı
7
Künye
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, S. T. S., Smejkal, K., Malanik, M., Sychrova, A., Barreca, D., Ziberna, L., Mahomoodally, M. F., Zengin, G., Xu, S., Nabavi, S. M., Shen, A. Z. (2019). Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics, 9(7), 1923-1951.
